OLZ/SAM + Olanzapine
Phase 3RecruitingInterest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia, Bipolar I Disorder
Trial Timeline
Jun 30, 2022 → Sep 1, 2026
NCT ID
NCT05303064About OLZ/SAM + Olanzapine
OLZ/SAM + Olanzapine is a phase 3 stage product being developed by Alkermes for Schizophrenia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05303064. Target conditions include Schizophrenia, Bipolar I Disorder.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05303064 | Phase 3 | Recruiting |
Competing Products
20 competing products in Schizophrenia